Online inquiry

IVTScrip™ mRNA-Anti-S, REGN-10933(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13810MR)

This product GTTS-WQ13810MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, REGN-10933(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ13810MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5839MR IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ChAglyCD
GTTS-WQ16008MR IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ZW-25
GTTS-WQ15698MR IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA VEGF Trap
GTTS-WQ242MR IVTScrip™ mRNA-Anti-B4GALNT1, 14.18 mAb(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 14.18 mAb
GTTS-WQ8426MR IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA HSP90mab
GTTS-WQ5974MR IVTScrip™ mRNA-Anti-IL6, CLLB8(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CLLB8
GTTS-WQ5392MR IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CD58-Fc
GTTS-WQ5549MR IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CDP7657
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW